Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
Hair loss discussion involves minoxidil, finasteride, and RU58841. Minoxidil non-responders may see results after adding stemoxydine due to increased enzyme presence.
User shows hair loss progress from NW4 to NW2.5 in 2.5 months using RU 8.5-9% daily and topical Dut .1% + RU 5% weekly. Discussion includes managing tension in African American hair and representation of different hair types.
Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.
The conversation discusses a user experiencing short, curly, wiry hair above and behind the ears, linking it to pattern baldness. The user suggests starting treatment early but personally chose not to pursue treatments like Minoxidil, finasteride, or RU58841 due to the hassle.
Oleic acid and ethanol are being considered for hair regrowth, with some users planning to self-experiment. There is skepticism about their effectiveness, and ongoing use of treatments like finasteride and minoxidil is mentioned.
The user experienced dryness and shedding with topical minoxidil and switched to oral minoxidil 2.5mg, seeking advice on what to expect. They are concerned about scalp health and looking for others' experiences with this change.
The importance of lighting when taking progress pictures and discussing hair growth, as dramatic changes can be seen even without real improvements. The users also discussed methods such as Fin min and dermarolling for treating hair loss.
A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.
A user is considering switching from oral to topical treatments for hair loss due to side effects like watery semen and erectile dysfunction. They are currently using oral finasteride and minoxidil and are concerned about potential sexual side effects with topical use.
The conversation is about a female experiencing hair loss and seeking advice on why it's difficult to regrow hair. Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user seeks opinions on the effectiveness of these treatments.
People are discussing the effectiveness of Breezula for hair loss maintenance. Some individuals are using Breezula alone, avoiding finasteride, and one plans to use Breezula after a hair transplant.
The conversation discusses using a hair wax containing propolis and Eruca sativa seed oil for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.
A 17-year-old using 5% topical minoxidil experienced significant hair shedding after a year, possibly due to a "synchronization shed" and deficiencies in vitamin D and iron. Recommendations include continuing minoxidil, optimizing vitamin D and iron levels, and reducing tretinoin use if scalp irritation occurs.
The conversation is about a user inquiring about a hair loss treatment product that contains minoxidil, azelaic acid, retinol, and caffeine, and whether it is more effective than Regaine foam. No specific treatments or outcomes are discussed.
Minoxidil sulfate is considered for those unresponsive to regular minoxidil, with some trying a 10% formulation from Folligenz. Concerns exist about the product's stability and transparency, but some users report positive initial results.
Sulfur soap may help with hair thickening and reducing scalp inflammation, but it can cause dryness. Nizoral, containing ketoconazole, is noted for its potential to reduce seborrheic dermatitis but may also cause scalp dryness and hair loss.
A user with diffuse hair loss for a decade tried various treatments, including LLLT Helmet, supplements, topicals, and hair transplants. They found relief from scalp inflammation and itching using a topical solution made from crushed Xeljanz pills mixed with ethyl alcohol.
The user discusses using essential oils like peppermint, rosemary, tea tree, and lavender to improve hair thickness and seborrheic dermatitis. They plan to add RU58841 to their routine and seek advice on using it alongside the essential oils without interference.
The trichologist avoids recommending Minoxidil, focusing instead on changing medications monthly for seborrheic dermatitis, resulting in only slight improvement in hair quality and loss. The user is considering starting Minoxidil independently due to slow progress and personal distress.
The conversation is about a user's 3-month hair regrowth progress using finasteride, minoxidil, and a 0.5mm dermaroller, with recent addition of caffeine shampoo. Users are responding positively and inquiring about application methods.
A user is using a compounded hair loss treatment with 5% minoxidil, 0.005% finasteride, and 0.01% tretinoin but is experiencing issues with residue and greasiness. They are inquiring if using the treatment five times a week instead of daily will still be effective.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.